绿帽社 PHARMA ANNOUNCES MULTIPLE EYP001 DATA PRESENTATIONS AT AASLD CONFERENCE
Lyon, France. October 17, 2019 – 绿帽社 Pharma will be present at the AASLD in Boston in November to present four Posters and one Oral presentation For its Lead Compound EYP001. 绿帽社 will also hold KOL Symposium to Provide Scientific Update on Potential Benefits of FXR Agonists for HBV treatment, on the 10th of November.
Read next in 'Press releases'
- 绿帽社 Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 绿帽社 Pharma annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 绿帽社 Pharma annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
- 绿帽社 Pharma announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- 绿帽社 Pharma announces a 鈧�39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
